IL-2 increased RANTES production and CD25 expression in cultured PBMCs only from antiretroviral treated HIV-1+ patients with detectable viral loads

International Immunopharmacology

Volumn 6, Issue 6, 2006, Pages 1034-1038

  Lozano, José Manuel ^a,b   Kindelán, José María ^a   Cabello, Almudena ^a   Gonzalez, Rafael ^a   Solana, Rafael ^a   Peña, José ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b INSTITUT PASTEUR   (France)

Author keywords

CCR; CD25; Chemokines; HAART; HIV 1; IL 2; PBMCs; RANTES; RANTES and viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RANTES; INTERLEUKIN 2 RECEPTOR; LEUKOCYTE ANTIGEN; VIRUS RNA;

ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG EFFECT; GENETICS; METABOLISM; MONONUCLEAR CELL; VIROLOGY;

ANTIGENS, CD; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; RANTES; RECEPTORS, INTERLEUKIN-2; RNA, VIRAL; VIRAL LOAD;

EID: 33747177605     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.01.002     Document Type: Article

References (23)

1. Mellado M., Rodriguez-Frade J.M., Vila-Coro A.J., deAna A.M., and Martinez A. Chemokine control of HIV-1 infection. Nature 400 (1999) 723-724
2. Davey R.T., Chaitt D.G., Albert J.M., Piscitelli S.C., Kovacs J.A., Walker R.E., et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 179 (1999) 849-858
3. Kovacs J.A., Vogel S., Albert J.M., Falloon J., Davey R.T., Walker R.E., et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335 (1996) 1350-1356
4. Emery S., Capra W.B., Cooper D.A., Mitsuyasu R.T., Kovacs J.A., Vig P., et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis 182 (2000) 428-434
5. Zou W., Foussat A., Capitant C., Durand-Gasselin I., Bouchet L., Galanaud P., et al. Acute activation of CD8+ T lymphocytes in interleukin-2-treated HIV-infected patients. ANRS-048 IL-2 Study Group. Agence Nationale de Recherches sur le SIDA. J Acquir Immune Defic Syndr 22 (1999) 31-38
6. Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 95 (1998) 3857-3861
7. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P., et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270 (1995) 1811-1815
8. Picard L., Simmons G., Power C.A., Meyer A., Weiss R.A., and Clapham P.R. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol 71 (1997) 5003-5011
9. Cervia J.S., and Smith M.A. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis 37 (2003) 1102-1106
10. Kovacs J.A., Vogel S., Albert J.M., Falloon J., Davey R.T., Walker R.E., et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335 (1996) 1350-1356
11. Paxton W.A., Neumann A.U., Kang S., Deutch L., Brown R.C., Koup R.A., et al. RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis 183 (2001) 1678-1681
12. Zou W., Foussat A., Capitant C., Durand-Gasselin I., Bouchet L., Galanaud P., et al. Acute activation of CD8+ T lymphocytes in interleukin-2-treated HIV-infected patients. ANRS-048 IL-2 Study Group. Agence Nationale de Recherches sur le SIDA. J Acquir Immune Defic Syndr 22 (1999) 31-38
13. Abad L.W., Schmitz H.R., Parker R., and Roubenoff R. Cytokine responses differ by compartment and wasting status in patients with HIV infection and healthy controls. Cytokine 18 (2002) 286-293
14. Pandolfi F., Pierdominici M., Marziali M., Livia B.M., Antonelli G., Galati V., et al. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin Immunol 94 (2000) 153-159
15. Caggiari L., Zanussi S., Bortolin M.T., D'Andrea M., Nasti G., Simonelli C., et al. Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients. Clin Exp Immunol 120 (2000) 101-106
16. Zanussi S., Simonelli C., Bortolin M.T., D'Andrea M., Crepaldi C., Vaccher E., et al. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Clin Exp Immunol 116 (1999) 486-492
17. Weiss L., Donkova-Petrini V., Caccavelli L., Balbo M., Carbonneil C., and Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 104 (2004) 3249-3256
18. high regulatory cells in human peripheral blood. J Immunol 167 (2001) 1245-1253
19. Zhang H., Chua K.S., Guimond M., Kapoor V., Brown M.V., Fleisher T.A., et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4(+)CD25(+) regulatory T cells. Nat Med 11 (2005) 1238-1243
20. Oswald-Richter K., Grill S.M., Shariat N., Leelawong M., Sundrud M.S., Haas D.W., et al. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol 2 (2004) E198
21. Nixon D.F., Aandahl E.M., and Michaelsson J. CD4+CD25+ regulatory T cells in HIV infection. Microbes Infect 7 (2005) 1063-1065
22. Levy Y., Durier C., Krzysiek R., Rabian C., Capitant C., Lascaux A.S., et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 17 (2003) 343-351
23. Hengge U.R., Borchard C., Esser S., Schroder M., Mirmohammadsadegh A., and Goos M. Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy. AIDS 16 (2002) 151-160